Syndax Pharmaceuticals Statistics
Total Valuation
SNDX has a market cap or net worth of $1.96 billion. The enterprise value is $1.52 billion.
| Market Cap | 1.96B |
| Enterprise Value | 1.52B |
Important Dates
The next estimated earnings date is Thursday, August 1, 2024, after market close.
| Earnings Date | Aug 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SNDX has 84.99 million shares outstanding. The number of shares has increased by 22.72% in one year.
| Shares Outstanding | 84.99M |
| Shares Change (YoY) | +22.72% |
| Shares Change (QoQ) | +17.46% |
| Owned by Insiders (%) | 0.82% |
| Owned by Institutions (%) | 108.94% |
| Float | 84.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.99 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.93, with a Debt / Equity ratio of 0.00.
| Current Ratio | 8.93 |
| Quick Ratio | 8.85 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,078.08 |
Financial Efficiency
Return on equity (ROE) is -53.30% and return on invested capital (ROIC) is -53.41%.
| Return on Equity (ROE) | -53.30% |
| Return on Assets (ROA) | -48.50% |
| Return on Capital (ROIC) | -53.41% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.31M |
| Employee Count | 184 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.12% in the last 52 weeks. The beta is 0.94, so SNDX's price volatility has been similar to the market average.
| Beta (5Y) | 0.94 |
| 52-Week Price Change | +6.12% |
| 50-Day Moving Average | 20.86 |
| 200-Day Moving Average | 19.75 |
| Relative Strength Index (RSI) | 58.75 |
| Average Volume (20 Days) | 1,172,199 |
Short Selling Information
The latest short interest is 8.34 million, so 9.82% of the outstanding shares have been sold short.
| Short Interest | 8.34M |
| Short Previous Month | 9.92M |
| Short % of Shares Out | 9.82% |
| Short % of Float | 9.86% |
| Short Ratio (days to cover) | 6.58 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -263.45M |
| Pretax Income | -240.63M |
| Net Income | -240.63M |
| EBITDA | -239.53M |
| EBIT | -240.41M |
| Earnings Per Share (EPS) | -$3.23 |
Balance Sheet
The company has $443.38 million in cash and $1.39 million in debt, giving a net cash position of $441.99 million or $5.20 per share.
| Cash & Cash Equivalents | 443.38M |
| Total Debt | 1.39M |
| Net Cash | 441.99M |
| Net Cash Per Share | $5.20 |
| Equity (Book Value) | 491.89M |
| Book Value Per Share | 5.79 |
| Working Capital | 403.09M |
Cash Flow
| Operating Cash Flow | -204.92M |
| Capital Expenditures | n/a |
| Free Cash Flow | -204.92M |
| FCF Per Share | -$2.41 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SNDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.72% |
| Shareholder Yield | -22.72% |
| Earnings Yield | -12.27% |
| FCF Yield | -10.45% |
Analyst Forecast
The average price target for SNDX is $35.25, which is 52.73% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.25 |
| Price Target Difference | 52.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -38.52% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |